{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:22:09Z","timestamp":1790000529602,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R269-A15935"],"award-info":[{"award-number":["R269-A15935"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006304","name":"Aalborg Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.isci.2024.111026","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T22:07:07Z","timestamp":1727129227000},"page":"111026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Rasmus Virenfeldt","family":"Flak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Kofod-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj Dich","family":"S\u00f8lvsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintare","family":"Naujokaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Agger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens Tornby","family":"Stender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susy","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurids \u00d8stergaard","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Thorlasius-Ussing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-1228","authenticated-orcid":false,"given":"Morten","family":"Ladekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.111026_bib1","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.111026_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort","volume":"188","author":"Ta\u00efeb","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2024.111026_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918816281","article-title":"Immunotherapy and pancreatic cancer: unique challenges and potential opportunities","volume":"10","author":"Young","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.isci.2024.111026_bib4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2217\/imt-2019-0164","article-title":"Is immunotherapy the holy grail for pancreatic cancer?","volume":"11","author":"Andersson","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.isci.2024.111026_bib5","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The Role of Immunotherapy in Pancreatic Cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.isci.2024.111026_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/2326-6066.CIR-22-0379","article-title":"Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer","volume":"11","author":"Faraoni","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2024.111026_bib7","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2024.111026_bib8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.pan.2017.09.008","article-title":"Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients","volume":"17","author":"Giardino","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.isci.2024.111026_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/153303460700600401","article-title":"Irreversible Electroporation in Medicine","volume":"6","author":"Rubinsky","year":"2007","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.isci.2024.111026_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-201X.2003.01093.x","article-title":"Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research","volume":"177","author":"Gehl","year":"2003","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.isci.2024.111026_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/153303460700600106","article-title":"Irreversible Electroporation: A New Ablation Modality \u2014 Clinical Implications","volume":"6","author":"Rubinsky","year":"2007","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.isci.2024.111026_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.111026_bib13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","article-title":"A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma","volume":"168","author":"O\u2019Neill","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.isci.2024.111026_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12029-016-9876-7","article-title":"Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography","volume":"48","author":"Ahn","year":"2017","journal-title":"J.\u00a0Gastrointest. Cancer"},{"key":"10.1016\/j.isci.2024.111026_bib15","doi-asserted-by":"crossref","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes","volume":"11","author":"Kim","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2024.111026_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2024.111026_bib21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","article-title":"Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme","volume":"9","author":"Jan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib23","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s12885-022-09719-6","article-title":"Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study","volume":"22","author":"Zou","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2024.111026_bib25","doi-asserted-by":"crossref","first-page":"1652532","DOI":"10.1080\/2162402X.2019.1652532","article-title":"Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T\u00a0cell activation","volume":"8","author":"Scheffer","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.isci.2024.111026_bib26","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non\u2013Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2024.111026_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2018.06.012","article-title":"Plasmacytoid dendritic cell in immunity and cancer","volume":"322","author":"Mitchell","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.isci.2024.111026_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4049\/jimmunol.1901121","article-title":"Natural and Induced Tolerogenic Dendritic Cells","volume":"204","author":"Iberg","year":"2020","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib29","doi-asserted-by":"crossref","first-page":"893177","DOI":"10.3389\/fimmu.2022.893177","article-title":"Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas","volume":"13","author":"Judge","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib30","doi-asserted-by":"crossref","first-page":"e000204","DOI":"10.1136\/jitc-2019-000204","article-title":"In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma","volume":"8","author":"Baba\u010di\u0107","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.isci.2024.111026_bib31","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/1535-7163.MCT-19-0132","article-title":"Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value","volume":"18","author":"Music","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2024.111026_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","article-title":"Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer","volume":"159","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2024.111026_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2024.111026_bib34","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers13081935","article-title":"CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade","volume":"13","author":"Vackova","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2024.111026_bib35","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-21-2078","article-title":"SOX10 Regulates Melanoma Immunogenicity through an IRF4\u2013IRF1 Axis","volume":"81","author":"Yokoyama","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2024.111026_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12935-021-02037-0","article-title":"Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2024.111026_bib37","doi-asserted-by":"crossref","first-page":"810993","DOI":"10.3389\/fimmu.2022.810993","article-title":"Complement System: An Immunotherapy Target in Colorectal Cancer","volume":"13","author":"Talaat","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111026_bib38","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.isci.2024.111026_bib39","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.isci.2024.111026_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-023-03158-4","article-title":"Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade","volume":"23","author":"Sun","year":"2023","journal-title":"Cancer Cell Int."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422402251X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422402251X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:33:53Z","timestamp":1783384433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422402251X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S258900422402251X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.111026","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.111026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111026"}}